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The 80-kDa immediate-early regulatory protein IE2 of human cytomegalovirus (HCMV) functions as an essential positive
transactivator of downstream viral promoters, but it also specifically down-regulates transcription from the major immediate-
early promoter through a 14-bp DNA target motif known as the cis-repression signal (CRS) located at the transcription start
site. The IE2 protein purified from bacteria as a fusion product of either staphylococcal Protein A/IE2(290–579) or
glutathione-S-transferase (GST)/IE2(346–579) bound specifically to a [32P]-labeled CRS oligonucleotide probe in an in vitro
electrophoretic mobility shift assay (EMSA). In contrast, no direct interaction with the CRS probes could be detected with IE2
wild-type protein in extracts from infected or transfected mammalian cells or when synthesized by in vitro translation.
However, in vitro phosphorylation of GST/IE2(346–579) by incubation with either the catalytic subunit of protein kinase A
(PKA) or a HeLa cell nuclear extract strongly inhibited its DNA-binding activity. This process required ATP hydrolysis and
could be reversed by subsequent incubation with bacterial alkaline phosphatase. Importantly, dephosphorylation of the
constitutively expressed native IE2 protein present in a nuclear extract from the U373(A45) cell line unmasked a specific CRS
DNA-binding activity that could be supershifted with anti-IE2 monoclonal antibody (mAb). A series of high-molecular-weight
hetero-oligomeric DNA-bound structures of intermediate mobility were formed in EMSA assays when a mixture of staphy-
lococcal Protein A/IE2 and GST/IE2 was coincubated with the CRS probe. Coincubation with a DNA-binding negative but
dimerization-competent GST/IE2 deletion mutant competitively inhibited DNA-binding by staphylococcal Protein A/IE2,
whereas coincubation with a GST/IE2 deletion mutant that lacked the ability to both dimerize and bind to DNA failed to
influence the mobility of the DNA-bound staphylococcal Protein A/IE2 protein. Therefore, IE2 appears to bind to DNA as a
higher-order oligomer in which the presence of subunits with mutant DNA-binding domains interferes with the overall
DNA-binding function. A series of point mutations introduced into each of nine conserved motifs throughout the DNA-binding
and dimerization domain, all of which abolish the ability of the transfected intact IE2 protein to autoregulate the MIE
promoter, also all lacked the ability to bind to CRS sequences as GST/IE2(346–379) fusion proteins. Detailed analysis of point
mutations in the 14-bp CRS target DNA binding motif revealed that IE2 binds in a relatively sequence-independent manner
to 10-bp-long A/T-rich DNA elements bounded on each side by CG dinucleotides. Moreover, the A/T-rich minor groove
binding agent distamycin, but not the G/C-rich minor groove binding agent chromomycin-A3, actively competed with IE2 for
binding to the CRS motif in a dose-dependent fashion. In conclusion, IE2 binds preferentially as multimerized dimers to
A/T-rich sequences in the minor groove that are flanked on both sides by appropriately spaced CG dinucleotides, and
inhibition of the DNA-binding or oligomerization activity by PKA phosphorylation probably accounts for the inactivity of the
mammalian and in vitro translated forms of the protein. © 1998 Academic Press
INTRODUCTION
The first hints that the 80-kDa IE2 transactivator/re-
pressor protein encoded by the major immediate-early
(MIE) gene of human cytomegalovirus (HCMV) might be
a sequence-specific DNA binding protein came from the
results of transient cotransfection assays, which identi-
fied a transferable 14-bp target response element re-
ferred to as cis-repression signal (CRS) that is necessary
for negative autoregulation of the MIE promoter and has
a ;2-fold axis of symmetry (Cherrington et al., 1991; Liu
et al., 1991; Pizzorno and Hayward, 1990; Pizzorno et al.,
1988). However, there have been no reports of a direct
interaction of the mammalian IE2 protein with CRS DNA
in standard in vitro electrophoretic mobility shift assays
(EMSAs), although several groups found that bacterially
expressed recombinant IE2 can bind to the CRS motif
with high affinity (Chiou et al., 1993, Furnari et al., 1993;
Lang and Stamminger, 1993; Macias and Stinski, 1993).
This binding interaction required only the C-terminal seg-
ment of IE2 from codons 290–579 and was detected only
in the presence of poly(dA-T)/(dA-T) competitor DNA but
was inhibited by the poly(dI-C)/(dI-C) copolymer, which is
more routinely used as a nonspecific competitor in such
assays. Curiously, in vitro translated IE2, which proved to
be a dimer in solution, also failed to bind to the CRS
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target DNA (Chiou et al., 1993). In contrast, the ability of
the IE2 protein to target specifically to the CRS target site
proved to be readily demonstrable in vivo in a one-hybrid
yeast genetic assay (Ahn et al., 1998).
Despite several additional analyses of the ability of the
bacterially expressed IE2 to bind to related target DNA
sites in some HCMV delayed-early promoters (Arlt et al.,
1994; Lang and Stamminger, 1994, Schwartz et al., 1994;
Scully et al., 1995; Wu et al., 1993), no one has yet shown
site-specific binding with the eukaryotically expressed
IE2 protein obtained from either virus-infected or DNA-
transfected cell extracts, and no clear consensus se-
quence for the target recognition site has yet emerged.
The apparent discrepancy between the in vitro DNA-
binding data for the bacterial and mammalian proteins,
compared with the in vivo ability of IE2 to down-regulate
MIE expression in transient cotransfection assays, indi-
cates that much of the DNA-binding activity of IE2 in
mammalian cells may be masked or regulated by cellular
factors, either through protein–protein contacts or
through secondary modifications such as phosphoryla-
tion. We also suggested previously based on the prop-
erties of OCT-2/IE2 fusion proteins that the intact IE2
protein might undergo intramolecular conformational
changes in which the N-terminus could potentially mask
the DNA-binding domain (Chiou et al., 1993). In fact,
[32P]-labeled IE2 protein can be detected in the nucleus
at all times throughout infection (Hermiston et al., 1987;
LaFemina and Hayward, 1983; Pizzorno et al., 1991;
Plachter et al., 1993; Stenberg et al., 1985, 1989), although
it also interacts with PML-containing nuclear bodies and
enters viral DNA replication compartments (Ahn and
Hayward, 1997). There also is evidence for the formation
of a stable protein–protein complex with the viral UL84
replication protein product at relatively late times after
infection (Samaniego et al., 1994; Sarisky and Hayward,
1996, Spaete and Tevethia, 1994).
The boundaries of the CRS target DNA sequence for
functional IE2-mediated down-regulation were initially
defined by deletion and mutation analysis of the MIE
transcriptional start site region in transient cotransfec-
tion assays with MIE promoter-driven CAT-reporter
genes (Cherrington et al., 1991; Liu et al., 1991; Pizzorno
and Hayward, 1990) and later by in vitro DNase I protec-
tion and metal binding analysis of DNA-bound bacterially
expressed IE2 protein (Lang and Stamminger, 1993,
1994). These studies all consistently revealed a deduced
14-bp minimal CRS recognition motif of CGTTTAGT-
GAACCG. The partially palindromic structure of this motif
is consistent with the dimeric character of the in vitro
translated IE2 protein as demonstrated by the formation
of stable heterodimers by crosslinking and immunopre-
cipitation with different-sized cotranslated subunits
(Chiou et al., 1993; Furnari et al., 1993). Our recent yeast
two-hybrid protein interaction mapping data (Ahn et al.,
1998) also confirm that like many other viral and cellular
transcription factors with palindromic DNA contact sites,
IE2 forms functional dimers or multiplies of dimers with
high affinity in vivo. The location of the CRS motif at the
transcription initiation site of the MIE promoter is partic-
ularly interesting with regard to the mechanism of the
negative autoregulation mediated by IE2. Simple binding
of IE2 to the CRS may be sufficient to cause a steric
hindrance in the pathway for assembly of the initiation
complex (Cherrington et al., 1991; Pizzorno et al., 1988),
although IE2 in its bound state might also be capable of
suspending the process of open complex formation by
interacting directly with various protein subcomponents
of the basal transcriptional machinery (Caswell et al.,
1993; Hagemeier et al., 1992; Jupp et al., 1993a; Macias
and Stinski, 1993; Wu et al., 1993).
In transient cotransfection assays, the intact 80-kDa
form of HCMV IE2 also behaves as a positive, but rela-
tively nonspecific, transactivator of downstream classes
of viral genes (Hermiston et al., 1987; Jupp et al., 1993;
Malone et al., 1990; Spaete and Mocarski, 1985), as well
as of many heterologous promoters (Hagemeier et al.,
1994, 1992, Monick et al., 1992; Pizzorno et al., 1988, 1991;
Yurochko et al., 1995). This property is consistent with a
role for IE2 during infection as the triggering regulatory
protein that directs transcription of the remainder of the
HCMV genome and creates a more favorable environ-
ment for lytic viral replication by directly altering the
properties of the host cell transcription machinery. The
specific negative autoregulatory function of IE2, which
presumably leads to a reduction in MIE gene expression
when no longer needed, may be important either during
the establishment of latency in nonpermissive situations
or at delayed-early and late times of infection when the
host cell machinery is required to perform the then more
important task of viral DNA replication, or both. Whether
the DNA-binding properties of IE2 also contribute to
positive regulation of those DE promoters that have up-
stream IE2 binding sites has not yet been fully resolved,
nor is the frequency of occurrence of high affinity IE2
binding sites in target HCMV promoters known.
Our goals in this study were to define more precisely
the consensus target DNA sequence for specific high-
affinity binding to the HCMV IE2 protein, to address
whether IE2 binds to DNA as a dimer or oligomer, and to
determine whether binding could be regulated in vitro by
protein phosphorylation and dephosphorylation events.
RESULTS
Lack of in vitro DNA-binding ability of IE2 expressed
in infected and DNA-transfected eukaryotic cells
Nuclear extracts prepared from HF cells infected with
HCMV (Towne) at high m.o.i. for 6, 12, 48, and 72 h failed
to reveal any IE2-specific DNA-binding activity in EMSA
experiments with a variety of wild-type [32P]-labeled CRS
oligonucleotide DNA probes of 26, 36, or 48 bp in length
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using either poly(dA-dT)/(dA-dT) or poly(dI-dC)/(dI-dC) as
nonspecific competitor DNA (not shown; Waheed, 1996).
Similarly, no specific CRS DNA-bound complexes were
found in nuclear extracts made from 293 cells transiently
transfected with the functionally active IE1 plus IE2 ex-
pression vector in plasmid pRL45 (data not shown), al-
though abundant expression of both the 68-kDa IE1 and
the 80-kDa IE2 proteins in these samples was confirmed
by IFA and Western blotting with a specific mAb. These
negative results were consistent with our previous in
vitro translation data (Chiou et al., 1993) but again con-
trasted with the ability to demonstrate CRS-mediated
down-regulation in transient cotransfection assays (Piz-
zorno and Hayward, 1990; Pizzorno et al., 1988) and the
ability to demonstrate CRS-specific DNA-binding by IE2
prepared from bacterial extracts or in vivo in yeast one-
hybrid assays (Ahn et al., 1998).
Characterization of wild-type and mutant
staphylococcal Protein A/IE2 DNA-binding domain
fusion proteins
To attempt to understand these differences, we
wanted to define the biochemical characteristics of the
bacterial IE2 CRS binding species in greater detail by
using both S. aureus and glutathione-S-transferase (GST)
fusion proteins containing the minimal DNA-binding do-
main of IE2 in EMSA experiments. Although we previ-
ously found that the GST/IE2(346–579) protein was fully
competent for CRS specific DNA binding in vitro, our
subsequent functional mapping data revealed that a do-
main between codons 313–346 was also required for
CRS target site recognition in one-hybrid interaction as-
says in yeast cells, as well as for negative autoregulation
in cotransfection assays (Ahn et al., 1998). Therefore, in
addition to needing to generate several distinguishable
forms of IE2 fusion proteins, we wanted to include this
further upstream domain in some of the fusion proteins
used.
Initially, the 28-kDa staphylococcal Protein A N-ter-
minal domain (STA) was joined to the C-terminal DNA-
binding domain of IE2 (Fig. 1A) to create STA/IE2(290–
579), which was purified from a crude bacterial extract
over an IgA–Sepharose affinity column, yielding a fu-
sion protein product of close to the expected size at 58
kDa (Fig. 1B, lane 1). Two mutant STA/IE2 fusion pro-
teins were also generated by introducing either a
4-amino-acid insertion at codon 542 in STA/IE2(290–
579ins14) or by adding a triple terminator at the same
site in STA/IE2(290–542tm). The validity of these con-
structions was confirmed by DNA sequencing and by
Western blotting, which revealed stable proteins of 58,
58, and 54 kDa, respectively (Fig. 1B, lanes 1–3). An
EMSA experiment that used a [32P]-labeled wild-type
CRS double-stranded 30-bp oligonucleotide probe
(LGH812/813) in the presence of poly(dA-dT)/(dA-dT)
as a nonspecific competitor confirmed specific bind-
ing with both the wild-type STA/IE2(290–579) fusion
protein and the 4-amino-acid insertion mutant STA/
IE2(290–579ins14) protein (Fig. 1C, lanes 1 and 2) but
not with the STA/IE2(290–542tm) truncation mutant
(lane 3). As expected, no IE2-specific DNA binding
was retained when poly(dI-dC)/(dI-dC) competitor was
used (lanes 4–6). As noted previously with GST/
IE2(346–579) (Chiou et al., 1993), the DNA-bound STA/
IE2(290–579) protein complex hardly entered a 4.5%
polyacrylamide gel (data not shown) and migrated
much slower than would be expected for even a dimer
of a 58-kDa protein in a 2% agarose gel (compared
with bound complexes of GST/YY1 and GST/EBNA-1
run in parallel).
A series of bacterial fusion proteins containing seg-
ments of IE2 joined to the 26-kDa N-terminal domain of
GST, including GST/IE2(346–579) and GST/IE2(388–579),
were described previously (Chiou et al., 1993), and a new
larger version extending forward to position 290 in GST/
IE2(290–579) was also generated specifically for these
studies (see below).
IE2 oligomerization is required for DNA binding
Although the in vitro translated IE2 protein forms
stable heterodimers in solution after cotranslation of
two different-sized C-terminal segments (Chiou et al.,
1993), we were unable to form similar heterodimers by
simple coincubation of mixtures of the preformed
dimers. This result presumably reflects the high sta-
bility of and lack of subunit exchange between the
dimers once formed. Because the dimerization domain
of IE2 maps between positions 388–542 by both in
vitro coimmunoprecipitation studies and in in vivo
yeast two-hybrid assays (Ahn et al., 1998; Chiou et al.,
1993) and therefore is nestled within the minimal DNA-
binding domain (position 313– or 346–579), most de-
letion or point mutations that abrogate dimerization
would be expected to affect DNA binding as well.
Consequently, in our initial attempts to examine the
role of IE2 dimerization or oligomerization in DNA
binding, equal amounts of the GST/IE2(290–579) and
GST/IE2(346–579) proteins that were each competent
for both DNA binding (B1) and dimerization (D1) were
coincubated with the CRS probe DNA (Fig. 2A, lanes 1
and 2). Surprisingly, simple mixing of the two different-
sized forms of bacterial GST/IE2 binding proteins pro-
duced apparent intermediate-sized hetero-oligomeric
bands (open arrow) by EMSA (lane 4), whereas coin-
cubation of GST/IE2(290–346) with GST protein had no
effect (lane 5).
Similarly, the mobility of some of the DNA-bound
complexes (open arrow) from a coincubated mixture of
the larger STA/IE2(290–579) protein with the smaller
GST/IE2(346–579) protein (Fig. 2B, lane 3) also proved
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to be intermediate between those obtained with the
two individual parent forms alone (referred to as SS
and GG; Fig. 2B, lanes 1 and 2). We interpret this result
to indicate that stable DNA-binding hetero-oligomers
containing dimeric subunits of both STA/IE2 and GST/
IE2 are formed (referred to as SG; open arrows). Fur-
thermore, the intermediate-sized SG complexes from
the coincubated mixture were supershifted with IgG
(specific for the staphylococcal Protein A portion of the
STA/IE2 protein) creating new complexes that mi-
grated considerably faster (SG-IgG, lane 4) than did
IgG supershifted complexes with the parent homoge-
neous STA/IE2(290–346) protein alone (SS-IgG, lane
5). As expected, the added IgG had no effect on the
mobility of the GST/IE2 protein alone (GG, lane 6).
Dominant inhibition of binding by a dimerization
competent DNA-binding negative mutant
Next, an N-terminal truncated version of GST/IE2(388–
579/B2D1) that lacks DNA-binding activity but can still
dimerize (Fig. 3A), as well as a triple-point mutant at
positions 442–444 within GST/IE2(346–579pmCM9/
B2D2), which was known to disrupt both the dimeriza-
tion and the DNA-binding domain in yeast assays, were
each tested for in vitro DNA-binding ability both before
and after coincubation with the larger STA/IE2(290–579)
fusion protein. Confirmation of the correct size and sta-
bility of the two purified mutant GST proteins compared
with the parent version was obtained by Western blotting
(Fig. 3B). GST/IE2(346–579) and GST/IE2(346–
579pmCM9) both produced intact 48-kDa bands that
FIG. 1. Direct DNA-binding activity of the E. coli expressed staphylococcal Protein A/IE2 fusion protein. (A) Schematic representation of the
primary structure of the bacterially expressed STA/IE2(290–579) fusion protein in plasmid pMP40 carrying the C-terminal half of IE2 exon 5.
Mutants carrying either an in-frame 4-amino acid insertion at the StuI site at position 542 as STA/IE2(290–579ins14) in plasmid pIW17 or a triple
terminator signal insertion at the same position STA/IE2(290–579tm) in pIW18 are also shown. Closed circles indicate nuclear localization
signals (NLS); hatched bar, activation domains. (B) Western blot analysis showing IgG–Sepharose affinity-purified forms of the three versions
of STA/IE2(290–579) described above after SDS–PAGE. The ;55-kDa proteins (arrows) were detected directly by incubation with HRP-
conjugated IgG. Lane 1 indicates STA/IE2(290–579); lane 2, STA/IE2(290–579ins14); lane 3, STA/IE2(290–579tm). (C) Autoradiograph results of
an EMSA experiment showing the direct DNA binding to CRS of STA/IE2(290–579) and STA/IE2(290–579ins14) but not by STA/IE2(290–
579tm542), in the presence of 40 mg/ml poly(dA-dT)/(dA-dT) (lanes 1–3) or poly(dI-dC)/(dI-dC) (lanes 4–6) as nonspecific competitor DNAs.
Approximately 250 ng of STA/IE2(290–579) protein (lanes 1 and 4), STA/IE2/(290–579ins14) protein (lanes 2 and 5), or STA/IE2/(290–579tm542)
protein (lanes 3 and 6) was added to the DNA-binding reaction mixture. The wild-type CRS oligonucleotide probe (LGH812/813) was labeled
with [a-32P]dATP and added to the binding reactions before DNA–protein complexes were resolved on a 2% TBE–agarose gel. S/IE2 indicates
the position of bound STA/IE2 protein; U, unbound.
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were detected with both the anti-GST and the anti-IE2
(P3) antibodies, whereas GST/IE2(388–579) produced a
42-kDa band detectable only with the GST mAb but not
by P3, which recognizes IE2 amino acids 367–382.
The results of an EMSA experiment (Fig. 3C) revealed
that when incubated with the wild-type DNA-binding
form of GST/IE2(346–579/B1D1), the mobility of the DNA-
bound STA/IE2(290–579/B1D1) version was again al-
tered to give complexes at intermediate positions (SG,
lane 6) between that of the original homogeneous larger
version (SS, lanes 1 and 5) and that of the homogeneous
smaller GST/IE2(346–579) version (GG, lane 2). However,
binding of the staphylococcal Protein A form was greatly
diminished when coincubated with the DNA-binding
negative, but dimerization-competent, GST/IE2(388–579/
B2D1) fusion protein (lane 7), whereas coincubation with
the dimerization and DNA-binding negative triple-point
mutant version of GST/IE2(346–579pmCM9/B2D2) did
not have any effect on the binding of STA/IE2(290–579)
(lane 8). These results both confirmed the existence of
hetero-oligomers and suggested that mixed multimeric
complexes containing some dimer subunits that lack the
DNA binding domain do not stably recognize the palin-
dromic CRS motif. Furthermore, the point mutant form of
IE2 that was unable to dimerize must also have been
unable to form oligomers.
Similar results were obtained when increasing
amounts (100, 250, and 500 ng) of the GST/IE2 iso-
forms were used to influence the DNA-binding pattern
of the STA/IE2 form (Fig. 3D). Under these conditions,
the mobility of the upper bound form of STA/IE2(290–
579) gradually changed from the SS to the faster mi-
grating SG pattern in the presence of the smaller
wild-type B1D1 form of GST/IE2 (Fig. 3D, panel A,
lanes 1–4) but did not do so in the presence of the
DNA-binding negative and dimerization-negative
B2D2 mutant form (panel C, lanes 11–14), whereas in
contrast, the SS form gradually disappeared in the
presence of the non-DNA-binding but dimerization-
positive B2D1 mutant (panel B, lanes 6–9). Signifi-
cantly, the dose-response experiment appears to
show a series of multiple intermediate-sized hetero-
oligomers (Fig. 3D, panel A, lanes 1–5), implying that
the stoichiometry of the structures may be quite large.
FIG. 2. Formation of DNA-bound STA/IE2 and GST/IE2 hetero-oligomers. (A) Autoradiograph results of an EMSA experiment suggesting the
formation of intermediate-sized GST/IE2 hetero-oligomers with the CRS DNA probe. Lane 1 indicates GST/IE2(290–579) alone; lane 2, GST/IE2(346–
579) alone; lane 3, GST alone; lane 4, coincubated mixture of GST/IE2(290–579) and GST/IE2(346–579); and lane 5, mixture of GST/IE2(290–579) and
GST. Open arrows denote novel intermediate-sized complexes present in lane 4. (B) Autoradiograph results of an EMSA experiment carried out with
a [32P]-labeled CRS oligonucleotide probe and the bacterial expressed STA/IE2(290–579) and GST/IE2(346–579) proteins either alone (lanes 1, 2, 5,
and 6) or coincubated together (lanes 3 and 4). IgG was added to supershift the DNA-bound STA/IE2 subunits present in staphylococcal Protein
homo-oligomers (SS) or hetero-oligomers (SG) in lanes 4–6. SS indicates STA/IE2 homo-oligomers; GG, GST/IE2 homo-oligomers; SG, STA/IE2:
GST/IE2 hetero-oligomers; SS-IgG, shifted homo-oligomer STA/IE2–IgG complex; and SG-IgG shifted hetero-oligomer STA/IE2 and GST/IE2–IgG
complex.
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FIG. 3. Formation of DNA-bound hetero-oligomers requires an intact dimerization domain. (A) Schematic representation of the various STA/IE2 and
GST/IE2 fusion proteins used. The parent wild-type GST/IE2(346–579/B1D1) gene encoded in pCJC176 has intact DNA-binding and dimerization
functions. The N-terminal truncated form GST/IE2(388–579/B2D1) in pCJC177 does not bind to DNA but still dimerizes in solution, whereas the
triple-point mutant at codons 442–444 (FLM–A*S*A*) version GST/IE2(346–579pmCM9/B2D2) in pCJC209 fails to bind or dimerize. The primary
structure of the long STA/IE2(290–579) form is also shown for comparison. Closed circles indicate NLS; hatched bar, activation domains; , position
of triple-point mutation. (B) Western blot analysis showing the GST affinity-purified forms of the three versions of GST/IE2(346–579) described above
after SDS–PAGE. The proteins were detected by incubation with anti-GST mAb and HRP-conjugated anti-mouse IgG (lanes 1–3) or anti-IE2 P3
antipeptide antibody and HRP-conjugated anti-rabbit IgG (lanes 4–6). Lanes 1 and 4 indicate wild-type GST/IE2(345–579/B1D1); lane 2, GST/IE2(388–
579/B2D1); and lanes 3 and 6, GST/IE2(346–579pm/B2D2). (C) Evaluation by EMSA of DNA binding by mutant forms of GST/IE2(346–579) and their
ability to form heterodimers with STA/IE2 using a [32P]-labeled CRS DNA probe. Lane 1 indicates STA/IE2(290–579) alone; lane 2, GST/IE2(B1D1)
alone; lane 3, GST/IE2(B2D1) alone; lane 4, GST/IE2(B2D2) alone; lane 5, STA/IE2 coincubated with STA/IE2; lane 6, STA/IE2 coincubated with
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The catalytic subunit of cyclic AMP-dependent
protein kinase can phosphorylate recombinant GST/
IE2 in vitro
Inspection of the amino acid sequence of the C-termi-
nal half of IE2 exon 5 (codons 290–579) indicated the
presence of potential conserved target sites for several
important protein kinases, including the cyclic AMP-de-
pendent protein kinase-A (PKA) located near the N-ter-
minal boundary of the DNA-binding domain and encom-
passing the second nuclear localization signal (NLS-2).
These sites 328 -KKKSKRTS-335 or 366-SRMFRNTNRS-
375 in HCMV IE2 and the equivalent sites KKTKTTKRIT or
SRMFRMTNRS in SCMV IE2 (Chang et al., 1995) have
potential consensus PKA target motifs (e.g., RRXS/T,
R/KXS/T, or R/KXXS/T). The Escherichia coli-expressed
GST/IE2(346–579) protein was incubated with 1 U of PKA
in the presence of [32P]-radiolabeled g-ATP and then
subjected to SDS–PAGE. The results showed that PKA
efficiently labeled two protein bands, including the intact
48-kDa species in the GST/IE2(346–579) preparation in
the presence of Mg21 and ATP (Fig. 4A, lane 1), whereas
no labeling was observed in the absence of PKA (lane 2)
or in the presence of EDTA (lane 3). GST alone was used
as a negative control (lane 4).
Next, three different C-terminal fragments of the IE2
fusion protein, namely GST/IE2(290–579), GST/IE2(346–
579), and GST/IE2(388–579), along with GST alone and a
control GST/YY-1 fusion protein, were used to roughly
map the N-terminal boundary of the PKA target site. An
autoradiograph of the [32P]-labeled proteins revealed
four protein bands for GST/IE2(290–579), with the largest
being a presumably intact species of 60 kDa (Fig. 4B,
lane 1). Fewer labeled bands were observed when
amino acids 290–346 were removed (lane 2), and no
labeling was obtained when amino acids 346–388 were
also removed (lane 3), which is consistent with labeling
of both predicted motifs. A control GST/YY-1 sample was
also efficiently labeled (lane 5), but GST alone was not
(lane 4). Therefore, at least two PKA target sites are
located between IE2 positions 290–388, and there ap-
pear not to be any more between 388–579. The region
between residues 346–388 encompasses one end of the
minimal in vitro DNA-binding domain of IE2 and could
represent an attractive target site for regulation by PKA-
dependent phosphorylation in a way that might modulate
either DNA-binding or oligomerization. The other site
between 290–346 encompasses an NLS, which may par-
tially account for its necessary role in autoregulation and
GST/IE2(B1D1); lane 7, STA/IE2 coincubated with GST/IE2(B2D1), and lane 8, STA/IE2 coincubated with GST/IE2(B2D2). (D) Dose-dependent
formation of hetero-oligomers between STA/IE2 and the shorter GST/IE2 isoforms. 1, A constant amount (500 ng) of STA/IE2 was added to each lane.
Increasing amounts (100, 250, and 500 ng) of wild-type GST/IE2(B1D1) (lanes 2–4), GST/IE2(B2D1) (lanes 7–9), or GST/IE2(B2D2) (lanes 12–14) were
coincubated with STA/IE2 before addition of the probe. Lanes 5, 10, and 15 each contain 500 ng of the appropriate GST fusion protein alone. SS
indicates DNA-bound homo-oligomeric STA/IE2; GG, homo-oligomeric GST/IE2, and GS, mixed hetero-oligomeric STA/IE2–GST/IE2 complexes.
FIG. 4. Requirements for in vitro phosphorylation of GST/IE2 with PKA. (A) Autoradiograph results of 10% SDS–PAGE analysis of GST/IE2(346–579)
after incubation with the catalytic subunit of PKA (1 U/sample) in the presence of incubation buffer (10 mM Tris, pH 7.5, 1 mM MgCl2) and 1 mCi of
[g-32P]ATP. The reaction was stopped by the addition of 5 mM EDTA after 15 min at 37°C. Each sample contained 250 ng of GST/IE2 protein. Lane
1 indicates GST/IE2(346–579) plus PKA, ATP, and Mg21; lane 2, same as lane 1 but without PKA; lane 3, same as 1 but with EDTA added in place
of Mg21; and lane 4, same as 1 but with the parent GST protein in place of GST/IE2. (B) Autoradiograph results of 10% SDS–PAGE analysis showing
the PKA target site-dependent [32P]-labeled phosphorylation of various N-terminal truncated versions of GST/IE2. Lane 1 indicates GST/IE2(290–579)
in plasmid pCJC190; lane 2, GST/IE2(346–579) in plasmid pCJC176; lane 3, GST/IE2(388–579) in plasmid pCJC177; lane 4, GST alone; and lane 5,
GST/YY1. Phosphorylation reaction conditions were the same as in A, lane 1.
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for DNA targeting in yeast. Parallel incubation with either
casein kinase II or Cdc2 cell cycle kinase failed to yield
labeled products with GST/IE2(290–579) or its deletion
derivatives.
PKA-mediated in vitro phosphorylation of
GST/IE2(346–579) inhibits its DNA-binding activity
To examine the possible effect of phosphorylation on
the DNA-binding ability of GST/IE2, a similar PKA-medi-
ated phosphorylation reaction was carried out in the
presence of either unlabeled ATP or a nonhydrolyzable
form ([g-35S]ATP) under the same conditions. The PKA-
treated proteins were then subjected to DNA-binding
tests by EMSA (Fig. 5A). Binding of GST/IE2 to the wild-
type CRS oligonucleotide probe (LGH812/813) proved to
be severely inhibited by the presence of PKA plus ATP
(lane 3), whereas PKA plus [g-35S]ATP-treated GST/IE2
retained its DNA-binding activity (lane 4). However, the
DNA-binding pattern of bacterial GST/YY-1 fusion protein
sample used as a control (Gu et al., 1995) was essentially
unchanged by either of these treatments (lanes 7 and 8).
In addition, we asked whether the DNA-binding activity
of the bacterial IE2 fusion protein might be similarly
affected by kinases present in a crude HeLa cell nuclear
extract. A GST/IE2(346–579) protein sample incubated
with HeLa extract in the absence of added ATP gave
normal DNA-binding activity (Fig. 5B, lane 2). However,
incubation of a parallel sample in the presence of ATP
(lane 5), but not in the presence of nonhydrolyzable
[g-35S]ATP (lane 4), disrupted its ability to bind to the
labeled CRS DNA probe. In addition, an unidentified
nonspecific HeLa cell-binding activity (CF) present in the
absence of GST/IE2 (lane 1) bound more intensely after
incubation with ATP (lane 3). This factor is displaced from
the probe in the presence of specific CRS GST/IE2 bind-
ing protein (lanes 2 and 4). Therefore, it seems probable
that our in vitro phosphorylation with PKA mimics a
kinase activity present in mammalian cells that leads to
inhibition of IE2 binding.
Phosphatase treatment of both prephosphorylated
bacterial GST/IE2 and the mammalian form of IE2
restores their DNA-binding ability
To examine whether dephosphorylation of PKA-treated
GST/IE2(396–579) could restore its DNA-binding ability,
both the native untreated and prephosphorylated GST/
FIG. 5. PKA-mediated in vitro phosphorylation of GST/IE2(346–579) inhibits its DNA-binding activity. (A) Autoradiograph results of an EMSA
experiment performed with PKA-treated GST/IE2(346–579) (lanes 1–4). Similar amounts of PKA-treated GST/YY1 were used as a negative control
(lanes 5–8). Phosphorylation conditions were the same as for Fig. 4 except that unlabeled ATP was used. Note the greatly reduced binding in lane
3 in the presence of PKA and ATP compared with lanes 1 and 2 in the presence of PKA alone or ATP alone and the absence of an equivalent effect
on GST/YY1 (lane 7). Nonhydrolyzable [g-35S]ATP was added in place of ATP in lanes 4 and 8 as a negative control to show that the reaction required
phosphate transfer. All lanes contained protease inhibitor cocktail (1 mM pepstatin, 1 mM leupeptin, and 100 mM PMSF). The probe DNA used was
the [32P]-labeled annealed wild-type CRS 30-mer oligonucleotide pair (lanes 1–4) or a similar [32P]-labeled YY1 consensus motif (lanes 5–8). (B)
ATP-dependent inhibition of GST/IE2(346–579) binding to DNA after incubation with crude HeLa cell nuclear extract. Lane 1 indicates HeLa cell extract
alone; lanes 2–4, HeLa cell extract plus GST/IE2(346–579); lane 2, incubated in the absence of ATP; lane 3, incubated with unlabeled ATP added to
a final concentration of 100 mM; and lane 4, incubated with [g-35S]ATP in place of ATP as a negative control. The [32P]-labeled DNA probe used was
the annealed 30-mer wild-type CRS oligonucleotide pair (LGH812/813). CF denotes the position of a bound nonspecific cellular factor present in lane
1 that is increased in abundance after incubation with ATP (lane 3) but is detectable only in the absence of specific GST/IE2 binding.
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IE2 proteins were incubated with bacterial alkaline phos-
phatase (BAP) for 15 min at 37°C in the presence or
absence of 1 mM inorganic phosphate (an inhibitor of the
phosphatase activity). EMSA analysis of the untreated
and prephosphorylated proteins again showed an inhi-
bition of binding by treatment with PKA (compare Fig. 6A,
lanes 1 and 4). The experiment also revealed that phos-
phatase treatment restored the DNA-binding ability of
the nonbinding prephosphorylated IE2 (Fig. 6A, lane 5),
whereas the binding of the native bacterial GST/IE2 was
unaffected (lane 2). Furthermore, although incubation
with inorganic phosphate alone had no effect on DNA-
binding (lane 3), the restoration of binding by BAP treat-
ment was inhibited by inorganic phosphate (lane 6),
indicating a dependence on dephosphorylation rather
than some other change.
To address whether phosphorylation might be respon-
sible for inhibiting the mammalian IE2 protein–DNA in-
teraction, nuclear extracts were prepared from a stably
transfected NeoR astrocytoma cell line U373(A45) that
constitutively expresses both HCMV IE1 and IE2 (derived
from plasmid pRL45) (Yoo et al., 1996). The parent cell
line U373(AN) carrying SV2Neo vector DNA only was
used as a negative control. Phosphatase treatment of
both extracts with BAP was carried out for 30 min at
37°C. Both the untreated and phosphatase-treated ex-
tracts were then subjected to EMSA with the wild-type
CRS DNA probe. As before, no binding activity was
detected directly with the untreated A45 or AN extracts
(Fig. 6B, lanes 1 and 3), but a specific novel band was
obtained in the phosphatase-treated A45 extract (lane 7).
Importantly, the uncovered DNA-binding activity was su-
pershifted with an IE2-specific antipeptide antiserum
(P4) raised against exon 5 residues 542–553 (lane 8).
This antibody is known to recognize IE2 without interfer-
ing with DNA binding (Chiou et al., 1993). No similar
activity was recovered from the AN cell extract in the
presence or absence of the antibody (lanes 5 and 6) or
from the A45 cells in the absence of BAP (lane 4).
A 1-bp insertion within the CRS motif abolishes the
MIE down-regulation phenotype
Earlier functional data, obtained by mutational analy-
sis of sequential overlapping 3-bp changes, hinted at the
possible existence of a 2-fold axis of symmetry in the
target sequence for IE2 autoregulation, with positions
1–5 and 10–14 within the CRS motif forming a nearly
palindromic version of the half-site CG(G
T )TT (Pizzorno
and Hayward, 1990). In initial studies to define the IE2-
binding specificity, six 30-mer oligonucleotide probes,
some containing multisite transversions in either half or
the middle of the palindrome (Fig. 7A), were tested for
direct binding to the bacterial GST/IE2(346–579) protein
by EMSA (Fig. 7B). The results showed that compared
with the wild-type CRS probe (LGH812/813, lane 1), mul-
tiple basepair mutations to create FspI and KpnI sites in
either the left or right half-site (lanes 2 and 4) led to a
total loss of binding, whereas mutation of the central four
bases (lane 3) or of three bases flanking the 14-bp CRS
motif itself (lane 5) did not affect binding to any great
extent. As shown previously (Chiou et al., 1993), insertion
of a single extra G residue between positions 7 and 8 in
the center of the motif also led to a complete loss of
binding (lane 6).
To confirm that the loss of IE2 binding by these muta-
tions and by the single-base insertion at position 8 in the
CRS motif correlates with a functional change, the mu-
tant DCRS sites were placed close to their normal posi-
tion within an MIE-CAT target reporter gene and used for
IE2 cotransfection assays in Vero cells (Table 1). The
activity of the positive control wild-type MIE (2760/17)-
CAT promoter was down-regulated 14-fold by cotransfec-
tion with a wild-type IE1 plus IE2 effector plasmid
(pRL45), but the version containing the single-base
DCRS insertion mutation and both the left FspI (pm214/
210) and right (KpnI 25/11) substitution mutants, as
well as the negative control D214/17 CRS deletion,
were unaffected by cotransfection with the IE2 effector
plasmid. Therefore, even just a 1-bp insertion in the
center of the CRS motif totally abolishes both IE2 binding
and the negative autoregulation phenotype.
Amino acid point mutations throughout the conserved
220-amino-acid C-terminal domain of IE2 all abolish
DNA-binding ability
We previously pointed out a series of 12- to 25-amino-
acid-long motifs within the C-terminal DNA-binding do-
main of HCMV IE2 from codons 356–574 that are all
relatively well conserved in the equivalent regions of the
simian CMV IE2 proteins from both African green mon-
key CMV and rhesus CMV (Chang et al., 1995; Chiou et
al., 1993). Homology within these motifs referred to as
CM5 to CM13 ranges from 50% to 100% amino acid
identity with an average similarity of 80–85%. Only three
of these motifs (CM6, CM9, and CM10) are equally well
conserved in MCMV and RCMV, and only two (CM6 and
CM10) are at all well conserved in HHV6 and HHV7. The
N-terminal segments of the IE2 proteins are much more
diverged, with only four motifs (CM1–CM4) displaying
similar levels of homology even among the primate ver-
sions. Because only the outside boundaries had been
mapped previously, the question arose as to whether all
of the C-terminal CM blocks participate in DNA binding
and dimerization.
We previously generated both a set of triple-amino-
acid-point mutations in each CM motif and a series of
small internal in-frame deletions that remove individual
CM motifs within the wild-type IE2 genomic expression
vector pMP18. These mutated versions all produced sta-
ble proteins detectable by IFA in DNA-transfected cells,
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and all proved to both abolish the ability of IE2 to down-
regulate the MIE promoter in transient cotransfection
assays and lose the ability to target to CRS DNA in yeast
one-hybrid assays (Ahn et al., 1998). However, several
also gave aberrant intranuclear localization patterns and
may not have been available for DNA binding. Therefore,
to examine whether the individual CM point mutations all
directly affect DNA binding in vitro, a parallel set of
mutations were introduced into the GST/IE2(346–579)
background and tested for their ability to bind to CRS
DNA probes in EMSA experiments. Each mutant plasmid
produced a fusion protein of the expected size of close to
48 kDa. The results of one typical EMSA experiment are
shown in Fig. 7C. Each sample was incubated with either
a wild-type 30-bp CRS DNA probe or the single-base
insertion 31-bp DCRS probe and then fractionated
through a 4.5% polyacrylamide gel. Although, as ex-
pected, GST/IE2(346–579) bound specifically to the wild-
type CRS but not to the DCRS probe, none of the mutants
tested, with the possible exception of very weak residual
activity by CM5, bound to the CRS probe. The addition of
nuclear extracts from HeLa or CA46 lymphoblastoid cells
failed to provide any complementing factors for the mu-
tant GST/IE2 proteins (not shown).
Detailed mutational analysis of the CRS target IE2
binding site
To define the individual nucleotide requirements
within the CRS for interaction with IE2, a new series of 15
annealed synthetic 30-bp-long [32P]-end-labeled oligonu-
cleotide pairs carrying single base transversions (T to G
or C to A or vice versa) (Fig. 8A) were used as specific
probes for GST/IE2-binding assays. Autoradiographic
analysis and quantification of the results revealed that
none of the single-CRS-point mutations completely abol-
ished IE2 interaction (Fig. 8B). Transversion of any mem-
ber of the flanking CG pairs (i.e., positions 1, 2, 13, or 14
in the consensus 14-bp element) caused 60–90% de-
crease in binding, whereas transversion mutations at
positions 4, 5, 6, 10, or 11 each resulted in 60–75% loss
of DNA binding. However, the transversions at positions
7, 9, 12, or 15 had only 10–20% inhibitory effects, and the
FIG. 6. Dephosphorylation of mammalian IE2 and in vitro phosphor-
ylated GST/IE2 by BAP restores DNA-binding ability. (A) Autoradiograph
results of an EMSA experiment with a wild-type [32P]-labeled CRS DNA
probe and bacterial GST/IE2(346–579) after PKA phosphorylation and
subsequent dephosphorylation. Untreated GST/IE2 (lanes 1–3) and
prephosphorylated GST/IE2 (lanes 3–6) were used at 250 ng of protein
each. BAP at 5 U/sample was incubated along with the proteins for 15
min at 37°C (lanes 2, 5, and 6). No restoration of IE2-specific DNA-
binding was seen when 1 mM inorganic phosphate (PO4) was added
as a phosphatase inhibitor to the reaction mixture (lanes 3 and 6). All
DNA binding reactions contained 40 mg/ml poly(dA-dT)/(dA-dT). (B)
Unmasking of the DNA-binding ability of the intact wild-type 86-kDa IE2
protein stably expressed in a mammalian cell line. Lanes 1 and 2
indicate untreated extract (5 mg protein each) from U373(A45) cells
carrying SV2-NEO vector alone; lanes 3 and 4; untreated extract (5 mg
protein each) from U373(A45) cells carrying the IE2 expression plasmid
pRL45; and lanes 5–8, the same extracts as in lanes 1–4 above but after
treatment with BAP (5 U/sample) for 15 min at 37°C. For IE2-specific
supershifts, antipeptide antibody recognizing the P4 epitope between
amino acids (542–553) was added at a ratio of 1:50 to lanes 2, 4, 6, and
8. Note that a specific CRS binding activity and supershift were ob-
tained only in lanes 7 and 8.
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FIG. 7. Initial mutational analysis of the IE2 binding site (CRS). (A) Summary diagram depicting the relevant sequences of a set of six 30-bp-long
wild-type and mutant double-stranded synthetic oligonucleotide probes used for direct IE2 DNA binding by EMSA. Relative binding affinity is shown
as 11 (strong binding affinity), 1 (weak affinity), 1/2 (very low affinity), or 2 (undetectable binding). (B) Autoradiograph results of an EMSA
experiment showing binding of wild-type GST/IE2(346–579) to [32P]-labeled wild-type and multiple-point mutant CRS oligonucleotide probes to
delineate the core DNA recognition element of IE2. Lane 1 indicates wild-type CRS (LGH 812/813); lane 2, left half-site mutant (LGH 821/822); lane
3, central 4-bp mutant (LGH 883/884); lane 4, right half-side mutant (LGH 823/824); lane 5, 3-bp mutation outside CRS from T15 to A17 (LGH 881/882);
and lane 6, G711 insertion (1G) mutant (LGH 825/826). U indicates unbound probe; p, mutated nucleotides. (C) Mutations within each of the
conserved motifs in the IE2 DNA-binding domain abolish in vitro binding to the CRS autoregulatory target sequence. Autoradiograph of an EMSA
experiment with a series of partially purified mutant bacterial GST/IE2 fusion proteins. All samples were incubated with either the wild-type 30-bp
[32P]-labeled CRS DNA probe (LGH546/547) or the 31-bp insertion mutant DCRS probe (LGH548/549) and subjected to electrophoresis through a 4.5%
polyacrylamide gel. Lanes 1 and 13 indicate probe DNA only; lanes 2 and 14, wild-type parent GST/IE2(346–579); and lanes 3–12 and 15–24,
GST/IE2(346–579) proteins containing the indicated triple-amino-acid-CM-point mutations.
245REGULATION OF IE2 DNA BINDING FUNCTION
single-nucleotide changes at positions 3 and 8 de-
creased the relative binding by 30–40%.
To further elaborate on the role of the flanking CG
dinucleotide pairs, we also introduced single-base con-
servative mutations in either or both CG pairs (Fig. 8B).
An analysis of the binding affinity of such mutants in
EMSA assays in comparison with that of the wild-type
CRS probe showed that mutation of either or both CG
pairs in one half-site (while still retaining high GC char-
acteristics) was less deleterious (60% loss of binding)
than similar mutations in both halves. In fact, all five
mutations tested in which one (or two) G-to-C or C-to-G
changes were made on each side, resulted in a com-
plete loss of IE2-binding affinity (,1.5% of wild-type lev-
els). The introduction of an A or a T on one side had
slightly greater effects than a single G-to-C or C-to-G
mutation. These results support the great importance of
the flanking CG pairs for IE2 binding, which probably
explains the highly efficient inhibition of binding by the
poly(dI-dC)/(dI-dC) competitor.
More precise quantification was obtained in two sets
of competition assays, where 5-fold increasing doses of
each unlabeled oligonucleotide pair were used as com-
petitors against the [32P]-labeled wild-type CRS oligonu-
cleotide probe in EMSA experiments. In the first experi-
ment, transversion mutants of the flanking CG dinucle-
otides (C1, G2, C13, G14), as well as the central G9, C12,
and G711 insertion mutant, were used to compete
against the wild-type CRS oligonucleotide pair for IE2
binding (Fig. 9A). The flanking CG pair mutants (C1, G2,
C13, G14) displayed the least ability to compete for IE2
binding, whereas two more central transversions tested
(G9 and C12) displayed equivalent to wild-type activity. In
contrast, the G711 mutant produced no competitive ef-
fects at all. Similar observations were made when A/T-
to-C/G transversion mutants at positions T3, T4, A10, and
A11 were used as competitors (Fig. 9B). Transversions at
positions T3 and T8 displayed efficient competition for
IE2 binding, suggesting that these residues might not be
crucial for IE2 DNA contacts, whereas transversions at
position T4, A10, and A11 were poor competitors for IE2
binding, indicating that these residues were more impor-
tant in making DNA contacts with IE2. Overall, despite
extensive mutational analysis, we were unable to gener-
ate a precise consensus IE2-binding sequence because
none of the transversion mutations completely abolished
DNA binding. The general pattern appeared to be that
mutations that increased the A/T character of the middle
10 bases were better able to compete with the wild-type
CRS.
IE2 interacts with a variety of CG dinucleotide bound
A/T-rich sequences: similarities with minor groove
binding proteins
The above observations that single-base transversion
mutations within the central 10 bases leading to in-
creased A/T content of the CRS motif tended to have less
effect on the binding affinity of IE2 than did those leading
to increased G/C content prompted us to further inves-
tigate this property. A quantitative comparison of the
direct EMSA binding affinity of several selected CRS
transversion mutants relative to the wild-type CRS probe
again showed that the IE2 protein bound most avidly to
versions of the CRS with a high central A/T nucleotide
content (Fig. 10). For example, the changes T2 to G, T4 to
G, A6 to C, and A10 to C all decreased the relative
binding affinity by 35–70%, whereas G7 to T and C12 to A
had no effect. Note that a version that represents a
complete palindrome of the CGTTT half-site (C11–A) ac-
tually displayed a 15% greater binding affinity than the
wild-type CRS motif. Surprisingly, two highly mutated
TABLE 1
Disruption of IE2-Mediated Down-Regulation by a Single Base Insertion within the CRS Target Site
Target promoter mutations
(plasmid name) Effector
CAT activity (fold effect)
Expt. 1 Expt. 2
IE68(2760/17)-CAT Basala 37.4% 20.1%
(p760wt-CAT) IE1 1 IE2b 2.3% 216.43 1.65% 212.33
IE68pmCRS ins28 (G)-CAT Basal 95% 59%
(pMP76) IE1 1 IE2 96% 1.03 30% 22.03
IE68pmCRS 214/210-CAT Basal 96% 62%
(pMP77/FspI) IE1 1 IE2 97% 1.03 65% 1.03
IE68pmCRS 25/11-CAT Basal N.D.a 86%
(pMP52a/KpnI) IE1 1 IE2 N.D. N.D. 81% 1.03
IE68DCRS-CAT Basal 73% N.D.
(pMP21) IE1 1IE2 94% 1.23 N.D. N.D.
a Activity measured after transient expression in Vero cells.
b Provided by cotransfection with pRL45 plasmid DNA.
N.D., not determined.
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FIG. 8. Single-point mutation analysis of the CRS target binding motif. (A) One-basepair scanning transversion mutations. (Left) Schematic
representation of the individual sequences of the 16 mutations introduced into 30-bp-long double-stranded synthetic CRS motif oligonucleotides used
as [32P]-labeled probes in EMSA experiments to determine the core IE2 DNA-binding motif. (Right) Quantitative assessment of the direct IE2 binding
affinity for the wild-type and a series of single-point mutant transversions (2 3 104 cpm, or 20 fmol/reaction). Each bar represents the relative binding
measured as the percent activity (fraction of total cpm bound by IE2) for the mutant probe compared with the wild-type probe set at 100%. (B) The
CG dinucleotides flanking the CRS are critical for recognition by IE2. (Left) Schematic representation of the sequences of 11 single and multiple
mutations generated in the flanking CG dinucleotide sequences of the 30-bp synthetic CRS motif oligonucleotide probes used. (Right) Quantitative
analysis of IE2 binding capacity of the CG dinucleotide mutants. Each bar represents percent binding measured as the fraction of the total probe
present in the shifted bands with the mutant probe compared with that obtained with the wild-type probe. Asterisks denote the mutated bases.
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versions of the CRS motif in which a total of either five or
seven internal bases were all changed to A or T, creating
the sequences CGATATATATATCG and CGTTTTTA-
AAAACG, still retained close to 100% of the wild-type
binding affinity for IE2.
Previous experiments have shown that IE2 binding
is abolished by the presence of double-stranded
poly(dI-dC)/(dI-dC) but not by poly(dA-dT)/(dA-dT) as
the nonspecific competitor DNA (Chiou et al., 1993),
suggesting that sequence specific contacts with the
flanking CG pairs are more critical than those with the
central A/T-rich bases. To examine whether IE2 bind-
ing might involve minor-groove recognition, both dis-
tamycin, which binds to A/T-rich minor groove se-
quences, and chromomycin-A3, which interacts
strongly with G/C-rich minor-groove sequences, were
used as potential competitors for CRS interactions. We
observed that 10-fold increasing doses of distamycin
efficiently competed with IE2 for binding to the CRS-
labeled DNA probe (Fig. 11A, lanes 1–4), whereas
similar doses of chromomycin-A3 had no effect on IE2
binding (Fig. 11A, lanes 5–8). As a control for speci-
ficity, we also examined the effect of these drugs on
binding of the HSV immediate-early protein IE175 to its
specific ATCGTCN4CCG response element (Roberts et
al., 1988). Binding of this protein was not affected by
the presence of either of the minor groove binding
agents (Fig. 11A, bottom). A quantitative assessment
of the distamycin and chromomycin-A3 specific com-
petition against IE2 is shown in Fig. 11B. These results
imply that IE2 interaction with the A/T-rich internal
sections of the CRS occurs within the minor groove,
FIG. 9. Competition analysis of IE2 binding to CRS with the point mutant probes. (A) Dose-dependent competition by selected single-point mutant
oligonucleotides carrying C/G-to-A/T transversions. Fivefold increasing amounts of excess unlabeled wild-type (F) or point mutant C1 (f), G2 (), G9
(r), C12 (e), C13 (M), G14 (), and G711 Ins (E) synthetic oligonucleotide DNAs were used to compete for GST/IE2(346–579) protein binding against
the wild-type CRS probe (LGH 812/813) probe in EMSA experiments. Each point on the curve represents percent binding of radiolabeled DNA (cpm)
in the presence of a given amount of unlabeled competitor DNA. All samples included 40 mg/ml poly(dA-dT)/(dA-dT) as nonspecific competitor. (B)
Dose-dependent competition by selected single-point mutant oligonucleotide carrying A/T-to-C/G transversions. Fivefold increasing amounts of
excess unlabeled wild-type (F) or point mutant T3 (f), T4 (), T8 (r), A10 (), A11 (M), and 11 INS (E) oligonucleotides were used as in A.
FIG. 10. Preference of IE2 for A/T-rich sequences bounded by CG
dinucleotides. The diagram presents a sequence comparison of vari-
ous synthetic point mutant [32P]-labeled oligonucleotides used for mea-
surements of their relative binding affinity for recombinant GST/
IE2(346–579) in direct EMSA DNA-binding experiments. Relative bind-
ing values indicate the fraction of the shifted versus free probe
compared with the wild-type CRS probe. Note the relatively high bind-
ing affinity of novel versions of CRS in which the entire N10 central
segments consist exclusively of palindromic A/T-rich sequences.
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whereas IE2 interactions with the G/C-rich flanking
sections apparently do not occur within the minor
groove.
DISCUSSION
Role of phosphorylation in IE2 in vitro DNA-binding
activity
Despite its relatively abundant expression in infected
cells and the ability to negatively autoregulate reporter
genes in a CRS-dependent manner in transient expres-
sion assays, previous attempts to show in vitro se-
quence-specific DNA-binding activity of the IE2 protein in
extracts from mammalian sources, including in vitro
translated forms, have been unsuccessful (Chiou et al.,
1993; Waheed, 1996). Nevertheless, recombinant IE2 ex-
pressed in bacterial systems, including either full-length
or truncated C-terminal fragments of IE2 as STA/IE2 or
GST/IE2 fusion proteins and IE2 produced in a baculo-
virus system, are all competent for binding specifically to
CRS target DNA in vitro as detected by both DNA foot-
printing and EMSAs (Arlt et al., 1994; Chiou et al., 1993;
Lang and Stamminger, 1993; Macias and Stinski, 1993).
We also demonstrated recently that the intact IE2 protein
can target specifically to the CRS DNA sequence in yeast
one-hybrid genetic assays (Ahn et al., 1998). This situa-
tion obviously suggests that the bulk of the HCMV IE2
protein present in extracts from mammalian cells has its
DNA-binding activity masked in some way, either be-
cause it is blocked by binding to some other viral or
cellular proteins or by modifications such as phosphor-
ylation at key positions or because it is present in an
inactive masked conformation or an inappropriate oligo-
meric form. Interestingly, these properties of HCMV IE2
are quite novel for known herpesvirus DNA-binding pro-
teins and are not found for HSV IE175, EBVZTA, or EBV
EBNA-1, which are all efficiently recovered as in vitro
DNA-binding activities from DNA-transfected mamma-
lian cells.
Our results clearly indicate that phosphorylation is
likely to play a key role in regulation of the DNA-binding
function of IE2. In vitro phosphorylation by the PKA cat-
alytic subunit led to inhibition of the DNA-binding ability
of bacterial GST/IE2 fusion proteins carrying C-terminal
residues from either positions 290–579 or 346–579. The
lack of phosphorylation of the shorter GST/IE2 form car-
rying residues 388–579 indicated that the principal PKA
target sites map between IE2 residues 290–388, a do-
main that is involved in many critical functions, including
DNA binding, repression, and protein–protein interac-
tions with other viral and nuclear factors. This region
contains several putative target sites for PKA phosphor-
ylation in which the serines, threonines, and adjacent
positively charged residues are conserved among the
primate CMV IE2 sequences. We were unable to label
the same form of the protein with either casein kinase II
(CKII) or Cdc2 kinases in vitro, but it is conceivable that
other cellular kinases, such as protein kinase C, that
might recognize these or other target sites in IE2 might
take part in such a mechanism. Recently, Harel and
FIG. 11. The sensitivity of IE2 binding to distamycin resembles that of
a minor groove DNA-binding protein. (A) Binding site competition anal-
ysis of the affinity of GST/IE2(346–579) for the wild-type [32P] CRS DNA
probe in the presence of increasing doses of the A/T-rich minor groove-
binding peptide distamycin (10 nM to 1 mM, lanes 1–4) or with equimo-
lar amounts of the G/C-rich minor groove binding drugs chromomy-
cin-A3 (lanes 5–8). Note the lack of binding site competition by the
latter. (Bottom) Absence of any effect of either the minor groove binding
drugs distamycin (lanes 1–4) or chromomycin-A3 (lanes 5–8) on the
DNA-binding ability for the specific ATCGTCN4CCG motif of the intact
HSV IE175 protein expressed in transiently transfected 293 cells. Sam-
ples of the total 293 cell extract (1 ml/lane) were incubated with the
DNA-binding mixture plus specific probe (LGH47/48) before the addi-
tion of competitor drugs. (B) Quantification of the DNA binding of
GST/IE2 in the presence of increasing amounts of distamycin (E) and
chromomycin-A3 (F). Each point on the graph represents percent
binding (cpm of shifted vs free probe) at varying concentrations of the
drug.
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Alwine (1998) presented on extensive analysis of MAPK
phosphorylation of IE2 both in vitro and in vivo, but none
of the sites examined mapped within the N-terminal
domain of the protein. Note that the P3 antipeptide anti-
body directed to an epitope between codons 367–382 in
the same region also interferes with GST/IE2 DNA-bind-
ing ability, in contrast to the P4 polyclonal antibody (pAb)
directed at codons 540–564, which produces super-
shifted complexes (Chiou et al., 1993). However, obvi-
ously we do not know at present whether the phosphor-
ylation or P3 antibody binding leads to a direct inhibition
of DNA recognition rather then to blocking of the appar-
ently critical oligomerization properties.
Our demonstration that the IE2 DNA-binding interac-
tion can also be unmasked after phosphatase treatment
of both the in vitro PKA phosphorylated bacterial ver-
sions and the intact mammalian protein present in the
stably transfected U373(A45) cell line indicates that the
autoregulation phenotype of IE2 might be under the con-
trol of phosphorylation events associated with the host
signal transduction machinery. However, whether the
phosphorylated form retains the ability to function in
transactivation or autoregulation is still an open ques-
tion. When bound to the CRS motif, the nonphosphory-
lated IE2 protein might form a complex with the TBP-
associated DR1 protein (Caswell et al., 1996), thus pre-
venting the assembly of other transcription factors.
Phosphorylation of both proteins through signal trans-
duction cascades could disrupt TBP–DR1–IE2 associa-
tions as well as the DNA-binding ability of IE2, thus
resulting in derepression. The modulation of the DNA-
binding activity of IE2 by phosphorylation and dephos-
phorylation events in vivo may have important conse-
quences for the final outcome of CMV infection because
DNA binding by IE2 is a prerequisite not only for the
down-modulation of the MIE promoter but perhaps also
for subsequent up-regulation of early and late gene ex-
pression by IE2. Obvious precedents for the role of pro-
tein kinase phosphorylation in disassociating multisub-
unit protein complexes come from both the RB–E2F and
NFkB–IkB systems.
Role of dimerization and oligomerization in IE2 DNA-
binding activity
The role of dimerization in DNA binding has been the
topic of intense study for many transcription factors. The
IE2 protein synthesized by in vitro transcription/transla-
tion has been shown to exist as a stable dimer in solu-
tion (Chiou et al., 1993), and high-affinity dimer or oli-
gomer formation has also been demonstrated in yeast
two-hybrid assays (Ahn et al., 1998), but whether IE2
binds to DNA as a dimer was unknown. The partial
dyad-symmetry of the IE2 response element supports
the notion that IE2 might also bind to DNA as a dimer,
and the unusually slow mobility of the IE2–DNA shifted
complex in polyacrylamide and agarose gels implied that
IE2 might be able to form even higher-order multimers at
its DNA contact site. Our results here have clearly indi-
cated that even the bacterial fusion versions of the IE2
C-terminal DNA-binding domain form higher-order mul-
timers of the stable dimers when bound to DNA. Further-
more, inclusion of subunits that can still dimerize but do
not bind DNA into the hetero-oligomeric complexes abol-
ished the ability of the multimers to bind to the CRS site.
We demonstrated previously that once formed, the IE2
homodimers synthesized in vitro are stable and are not
free to reassociate when mixed with homodimers con-
taining tagged subunits of a different size (Chiou et al.,
1993). Furthermore, we have found that in both the yeast
two-hybrid system (Ahn et al., 1998) and by in vitro pro-
tein–protein interaction assays between in vitro trans-
lated [35S]-labeled IE2 and GST/IE2, the affinity of IE2
C-terminal domain self-interactions is equally as strong
as those of the yeast SNF1–SNF4 interaction, the mam-
malian p53–p53 self-interaction, the Ad E1A–Rb interac-
tion, and both HSV IE110–IE110 and EBNA1–EBNA1
dimerization (C.-J. Chiou and G. S. Hayward, unpublished
data). Therefore, assuming that the subunits of the bac-
terial fusion proteins are also dimers that are unable to
exchange once they have been formed, the minimal
DNA-binding protein complexes must be at least tetram-
ers but are more likely octamers or dodecamers based
on the presence of several distinct intermediate-sized
hetero-oligomer bands in the EMSA patterns. Conceiv-
ably, the interference with binding produced by mixing
the non-DNA-binding dimers with those that are compe-
tent to bind could be because the former are unable to
oligomerize rather than being unable to recognize the
DNA. However, it also seems more likely that to be able
to have a negative effect at all, they must retain the ability
to interact with other dimers. Presumed conformational
differences between DNA-bound and unbound dimers
may also play a role within the larger multimeric com-
plexes. Note that because each type of homodimer pro-
duces a relatively sharp single DNA-bound complex, it
seems likely that only one particular higher-order com-
plex can bind (i.e., only octamers, not tetramers or 16-
mers). A recent demonstration by UV-crosslinking that
IE2 is in close contact with the DNA (Macias et al., 1996)
in the form of dimers, confirms the central tenet of our
model for palindromic sequence recognition (Chiou et
al., 1993; Pizzorno and Hayward, 1990), but is not incom-
patible with the concept that stable binding requires
additional multimerization. Our previous observation that
increasing amounts of P4 antibody added to GST/
IE2(346–579) produced multistep DNA-bound super-
shifted bands in EMSA assays could also support the
idea that IE2 may bind to DNA as a higher-order oligomer
(Chiou et al., 1993).
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The mode of DNA recognition by IE2
Our extensive target site mutagenesis data confirmed
that efficient binding of IE2 to the CRS target motif re-
quires a central 10-bp A/T-rich stretch of nucleotides
covering a full helical turn bounded by two CG dinucle-
otide pairs. Initial deletion mutation analysis of the CRS
motif led us to believe that both halves of the nearly
palindromic site may be essential for the binding by IE2
because multiple basepair transversion mutations in
each half-site completely abolished the down-regulation
phenotype (Pizzorno and Hayward, 1990). The signifi-
cance of spacing rather than the specific order of internal
nucleotides is also emphasized by our observation that
an insertion of a single extra G residue in the middle of
the palindrome completely abolished DNA binding, as
well as resulting in a total loss of functional autorepres-
sion, presumably because of its ability to disrupt the
alignment of the outside CG nucleotide pairs. Interest-
ingly, even a 4-bp central mutation of residues 6–10
(AGTG through GGGC) reduced binding only 5-fold. In
comparison, single transversion mutations of positions 1,
2, 4–6, 10, 11, 13, and 14 within the 14-bp CRS motif each
reduced in vitro binding to 10–40%, and many double
mutations within the flanking CG pairs reduced binding
to #1%. Conversion to a completely palindromic motif
increased binding affinity to 115% for the more A/T-rich
version CGTTTN4AAACG but reduced it to only 65% for
the more G/C-rich CGGTTN4AACCG version. Finally,
conversion of the entire central 10 bp to the repetitive
A/T-rich sequence ATATATATAT or TTTTTAAAAA failed to
reduce IE2 binding at all, in dramatic contrast to the
major effects achieved by altering the flanking CG
dinucleotides. Overall, our results from the point muta-
tion data and oligonucleotide competition analysis imply
that IE2 interacts with DNA in a far less stringent fashion
than is normally expected for sequence-specific DNA-
binding proteins and indicate that IE2 preferentially rec-
ognizes a 10-bp-long A/T-rich sequence flanked by CG
dinucleotides on either side.
An important factor in IE2 protein–DNA interactions is
the relatively high sensitivity toward the nonspecific
poly(dI-dC)/(dI-dC) competitor DNA that has routinely
been used in EMSAs to prevent nonspecific protein bind-
ing, whereas poly(dA-dT)/(dA-dT) competitor has little
effect (Chiou et al., 1993). Presumably this reflects stan-
dard sequence-specific recognition of the flanking CG
pairs but not of the central AT pairs. Lang et al. showed
that replacement of the central A-T nucleotide pairs with
I-C nucleotide pairs does not disrupt IE2–DNA interac-
tions, presumably because these changes preserve the
contacts with backbone phosphate groups within the
minor groove (Lang and Stamminger, 1994). Moreover,
our observation that the A/T-rich minor groove binding
peptide distamycin strongly competed with IE2 for bind-
ing to the CRS, whereas the G/C-rich minor groove bind-
ing peptide chromomycin-A3 did not, supports the con-
cept that IE2 binding is related to or analogous to that of
other A/T-rich minor groove binding proteins.
Known minor groove binding proteins include the TATA
binding protein (TBP), some HMG domain protein family
members such as LEF-1, TCF-1, and the male sex-deter-
mining factors SRY and SOX-4, as well as the bacterial
protein IHF-1. Shared properties common to such pro-
teins include interaction with A/T-rich DNA in the minor
groove with relatively loose sequence specificity and
competition by peptides such as distamycin that bind
specifically to A/T-rich oligonucleotides including d(CG-
CAAATTTGCG)2 and d(CGCGAATTCGCG)2, as well as
the ability to bind to irregular DNA structures and the
capacity to modulate DNA structure by bending. Many
members of this family act both as activators and repres-
sors of transcription. DNA bending induced by these
proteins can facilitate or disrupt the formation of higher-
order nucleoprotein complexes that are important for
maintenance of DNA architecture and the onset of tran-
scription and DNA replication. In the case of the YY-1
zinc finger protein, its ability to act as an activator or a
repressor depends on the nature of the induced bending
and the context of its binding sites (Natesan and Gilman,
1995). Therefore, it is tempting to speculate that binding
of IE2 to the minor groove of the CRS might induce a
direct local rearrangement in the DNA topology, resulting
in destabilization of the adjacent transcriptional machin-
ery in the initiation complex and hence down-regulation.
Consequences for IE2 promoter targeting and gene
regulation
Our findings about IE2 sequence recognition have
major implications for the identification and role of po-
tential additional IE2 binding sites in the HCMV genome.
Others have reported binding sites for IE2 detected by
DNA-footprinting in several downstream delayed-early
class HCMV promoters (Arlt et al., 1994; Schwartz et al.,
1994; Scully et al., 1995). So far all of these sites were
found in upstream promoter locations, and in general,
although they may contribute to positive regulation by
IE2, they appear to be dispensable for IE2 responsive-
ness. We have also identified four additional upstream
IE2 binding sites in the HCMV IES/US3 enhancer region
and found that they modulate IE2 responsiveness in a
complex cell-type specific fashion (Waheed, 1996). These
sites were not all predicted based on the original CRS
consensus motif (e.g., one site has a CGN11CG pattern),
but they fit well into the current modified model of pref-
erentially A/T-rich CRS-like core sequences bounded by
CG dinucleotides.
This model of a higher-order oligomeric structure for
DNA-bound IE2 might allow for the additional factor of
bridging between nonadjacent binding sites and contact
with multiple accessory proteins. Furthermore, well
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known precedents for functional DNA binding as tetram-
ers for p53 (Clore et al., 1994; Hupp and Lane, 1994;
Hupp et al., 1992) and as double hexamers for SV40 large
T-antigen (Parson et al., 1991) have been documented. In
fact, the tetramerization domain of p53 and the role of its
adjacent C-terminal conformation-modulating domain
(Hupp et al., 1992), which can regulate binding through
phosphorylation, RNA, or antibody binding and probably
also protein–protein interactions, appear to provide a
close parallel to the situation in HCMV IE2, where the
region between amino acids 313–388 adjacent to the
dimerization domain now appears to have many similar
modulatory features.
Nature of the DNA binding domain of IE2
We demonstrated previously that the in vitro DNA-
binding activity of GST/IE2(346–579) as assayed by
EMSA was abolished by N-terminal truncation to codon
388 or by C-terminal truncation to codon 542 (Chiou et
al., 1993). Furthermore, a set of internal deletions and all
10 different CM triple-amino-acid-point mutations tested
across this domain eliminated in vitro binding of GST-
fusion proteins, as well as abolishing autoregulation by
the intact mammalian expressed IE2 protein in transient
cotransfection assays (Ahn et al., 1998). Because both
the in vitro dimerization and yeast two-hybrid self-inter-
action properties remain intact in both the IE2(388–579)
and IE2(346–542) versions, we presume that both of the
additional domains between 346–388 and between 542–
579 contain crucial information for direct DNA recogni-
tion or perhaps oligomerization. Furthermore, functional
mapping studies revealed that extra amino acids be-
tween 312–346 are also essential for DNA binding in vivo
and for CRS-mediated negative autoregulation (Ahn et
al., 1998), although these are not required for in vitro DNA
binding with bacterial fusion proteins.
Curiously, the insertion of four in-frame amino acids at
position 542 in STA/IE2(290–579) did not disrupt DNA
binding, although truncation by insertion of a triple ter-
minator at the same site did do so. Note that this same
4-amino-acid insertion in the intact IE2 protein abolished
transactivation but not autoregulation (Waheed, 1996).
Furthermore, the 37-amino-acid block between 543–579
behaves as an independent transcriptional activator in
GAL4 domain swap assays, and its removal from wild-
type IE2 destroys both autoregulation and transactivation
(Pizzorno et al., 1991). However, replacement with the
powerful activator domain of VP16 failed to restore either
autoregulation or efficient transactivation. Therefore, re-
gardless of the identity of the contribution of the extreme
37-amino-acid C-terminus to DNA binding, it evidently
does not involve a contiguous domain crossing between
CM12 and CM13, and it is clearly different from the
requirements for transactivation.
The well-characterized minor groove DNA-binding
HMG domain encompasses peptide sequences such as
TPKRPRGRPKK, PRGRPKK, and PRGRP, of which the RGR
segment has been shown to be in contact with the minor
groove. HCMV IE2 contains the peptide TRRGRVK at
position 356–362, and the IE2 CM5 mutation at positions
358–360 spanning these residues RRGRVK to
RRA*S*A*K virtually abolished CRS-specific DNA binding
in vitro within GST/IE2(346–579). Similarly, amino acids at
position 376–378, which lie outside of the dimerization
region, appear to carry crucial DNA-binding information
because mutation of RSLEYK to RSA*S*A*K completely
abolished DNA binding. This is consistent with our pre-
vious evidence that the P3 antipeptide antibody gener-
ated against an epitope representing amino acids 367–
385 also inhibits IE2–DNA interactions (Chiou et al.,
1993). This region (CM6) is fully conserved among simian
as well as rodent versions of CMV IE2 and also in HHV6
IE2. The CM5 and CM6 domains are both dispensable
for dimerization in solution, and therefore their roles
must involve either direct DNA recognition or oligomer-
ization functions.
Interestingly, the basic DNA-binding domain of HMG
box-containing proteins that make contacts in the minor
groove have been shown to be regulated by phosphor-
ylation of a threonine residue by PKA and by cell cycle-
dependent Cdc-2 kinase, which results in severe impair-
ment of the DNA-binding capability of these proteins
(Reeves et al., 1991). It should be noted that unlike major
groove interactions, minor groove contacts are less strin-
gent and sometimes occur as mere tethering of the
protein to DNA, thus making it more susceptible to
changes in the overall charge of the DNA-binding amino
acid sequences. Finally, the motif GPRKKKSKR between
positions 322–330 of HCMV IE2 contains another puta-
tive positively charged sequence with a potential target
site for PKA that might be involved in regulating DNA-
binding activity or protein–protein interactions through
phosphorylation. This motif also acts as a nuclear local-
ization signal (NLS-2) (Pizzorno et al., 1991), and although
it lies outside the N-terminal boundary of the in vitro
DNA-binding domain, it is part of the extra domain be-
tween 314–346 that is needed for specific CRS DNA
interactions in vivo in a yeast one-hybrid system and is
essential for negative autoregulation in transient co-
transfection assays (Ahn et al., 1998).
MATERIALS AND METHODS
Cells and viruses
Adherent cells (HeLa, HF, U373, and Vero) were grown
in glutamine-supplemented DMEM plus 10% FCS at
37°C and 5% CO2. HCMV (Towne) infection of HF cells
was carried out with supernatant virus at an m.o.i. of
5–30 plaque-forming units/cell in cultures at 90% conflu-
ence. The cultures were washed with prewarmed me-
dium after a 2-h absorption step and were incubated at
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37°C before harvesting for nuclear extracts at 6, 12, 48,
or 72 h. The recovered cells were pelleted at 4°C and
5000 g for preparation of the whole-cell and nuclear
extracts for Western immunoblots and EMSAs.
U373(A45) cells are a stable NeoR human astrocytoma
cell line that received the cotransfected pRL45 plasmid
(encoding both MIE proteins) and constitutively ex-
presses high amounts of 72-kDa IE1 in all cells and small
amounts of 86-kDa IE2 in some cells, as judged by IFA,
Western blotting, and transient activation of an IE2-re-
sponsive target CAT reporter plasmid (Yoo et al., 1996).
Bacterial recombinant IE2 proteins
The bacterial staphylococcal Protein A/IE2(290–579)
fusion protein gene carried by plasmid pMP40 contains
an in-frame insertion of the C-terminal region of IE2
behind the 28-kDa IgG binding receptor of Staphylococ-
cus aureus (STA) in the parent temperature-sensitive
isopropyl-b-d-thiogalactopyranoside (IPTG)-inducible
vector pRIT-2T. Plasmids pIW17 and pIW18 were gener-
ated by in-frame insertion of a 12-bp BglII linker or an
XbaI triple terminator signal at the unique StuI site
(codon 492) in IE2 exon 5 of the plasmid pMP40. In
addition, a series of fragments of HCMV (Towne) IE2
were inserted as in-frame fusions behind the 26-kDa
GST domain from the mammalian GST in the pGEX-3X E.
coli vector system. Details of the construction of the
GST/IE2(346–579) and GST/IE2(388–579) proteins in
plasmids pCJC176 and pCJC177 have been given previ-
ously (Chiou et al., 1993). GST/IE2(290–579) was gener-
ated similarly as a BglII–EcoRI bounded PCR product
from pRL45 template DNA and inserted as an in-frame
fusion in the GST/BglII background plasmid pGH417.
The internal triple-amino-acid-point mutation GST/
IE2(346–579 pmCM9/B2D2) in pCJC209 was con-
structed by in-frame joining of two PCR products con-
taining IE2 codons 346–443 (BglII–NheI) and 443–579
(NheI–BglII) from pRL45 template DNA to create a 442-
FLM-444-to-442-A*S*A*-444 mutation at the junction and
then placing this as a BglII–BglII fragment in-frame be-
hind GST in pGH417. Finally, a complete set of GST/
IE2(345–579) triple-point mutations scanning the con-
served domain motifs CM5–CM13 was generated in a
similar way, although FspI was used as the junction site
in some, producing A*C*A* instead of A*S*A* mutations.
Those used here included GST/IE2 pmCM5(358 GRV/
ASA) in pCJC205, GST/IE2pmCM6 (376 LEY/ASA) in
pCJC206, GST/IE2pmCM7 (402 MQV/ASA) in pCJC207 in
GST/IE2pm CM8 (417 HEV/ASA in pCJC208), GST/
IE2pmCM9 (442 FLM/ASA in pCJC209), GST/
IE2pmCM9/10 (172 WSL/ACA) in pCJC219, GST/
IE2pmCM10 (487 SDY/ACA) in pCJC210, GST/IE2
pmCM11(516 FPK/ACA) in pCJC211, GST/IE2pmCM12A
(535 PIY/ACA) in pCJC212, and GST/IE2pmCM12B (547
GQF/ACA) in pCJC213. GST/YY1 contains the intact YY1
cDNA as a fusion with GST in pGEX-2T (Gu et al., 1995;
Shi et al., 1991)
Mammalian reporter and expression plasmids
Genomic plasmid pRL45 containing a 6.7-kb EcoRI-to-
SalI fragment of HCMV (Towne) DNA (map coordinates
168817–175524) represents our standard wild-type MIE
effector plasmid that expresses high levels of the spliced
functional forms of both the 68-kDa IE1 (UL122) and
80-kDa IE2 (UL133) mRNA and proteins after transient
DNA transfection driven by the complete HCMV MIE
promoter/enhancer region in its natural surrounding se-
quence context (LaFemina et al., 1989; Pizzorno et al.,
1988). The target MIE promoter-driven CAT reporter
genes used for negative autoregulation studies included
the standard wild-type IE68(2760/17)-CAT gene in plas-
mid p760wtCAT and its CRS deletion mutant IE68(2760/
213) DCRS-CAT in plasmid pMP21 as described previ-
ously (Pizzorno and Hayward, 1990). In addition, triple-
point mutant CRS motifs were generated by inserting
30-bp annealed oligonucleotide pairs between the
unique SacI and BamHI sites in pMP21 to generate
IE68(2760/213) (pmCRS25/11 KpnI)-CAT in pMP52a,
IE68(2760/213) (pmCRS214/210 FspI)-CAT in pMP77,
and IE68(2760/213) (pmCRS 11/ins)-CAT in pMP76.
Synthesis and purification of IE2 fusion proteins
Overnight cultures of E. coli JM101 harboring the
pGEX-3X-based fusion gene plasmids were diluted 1:10
in 100 ml of Luria’s broth (LB) medium containing 100 mg
of ampicillin/ml and grown for 1 h at 37°C. After induction
with 0.1 mM IPTG, the bacteria were grown continuously
for an additional 5 h before harvesting at 3000 g for 10
min at 4°C. The cell pellets were resuspended in 5 ml of
PBS–1% Triton X-100 containing 1 mM phenylmethylsul-
fonyl fluoride (PMSF) and lysed by sonication at 0°. Clear
supernatant containing soluble GST/IE2 fusion proteins
was recovered from the bacterial debris after centrifuga-
tion at 10,000 g for 30 min at 4°C. The supernatant was
gently mixed with 300 ml of preswollen glutathione–
agarose bead slurry (Pharmacia) and incubated with
constant shaking for 1 h at 4°C before pelleting. The
pellet was washed three times with PBS-A. Fusion pro-
teins were eluted by the addition of 300 ml of 50 mM
Tris–HCl (pH 8.0) plus 5 mM glutathione and analyzed on
SDS–polyacrylamide gels. Proteins were visualized by
Coomassie blue staining and stored at 280°C for further
use.
For the purification of the staphylococcal Protein A/IE2
fusion proteins, 1:10 diluted overnight bacterial cultures
of E. coli N4830–1 harboring pRIT-2T-based plasmids
were grown at 28°C with rigorous shaking until log
growth phase was reached (after 4 h), when an equal
volume of fresh LB medium prewarmed at 55°C was
immediately added to the 28°C culture to inactivate the
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temperature-sensitive CI
857 repressor. The bacterial cul-
tures were grown for an additional 3 h at 42°C with
constant shaking before harvesting at 5000 g to recover
the bacterial cell pellet. The pellet was resuspended, and
the cells were lysed as described above for the GST
fusion proteins. The clear supernatant was mixed with
200 ml of pre-equilibrated IgG–Sepharose slurry (Phar-
macia) and incubated with constant shaking for 1 h.
Staphylococcal Protein A/IE2 protein-bound slurry was
extracted from the remainder of the incubation mixture
and washed with 5 mM N-acetate (pH 5.0) to remove
nonspecifically bound proteins. The fusion proteins were
recovered from the IgG beads by elution with 300 ml of
0.5 M acetic acid (pH 3.5) and immediately dialyzed
against Tris–HCl (pH 8.0) to bring the pH back to the
neutral range.
Western immunoblots
Protein samples were suspended in an equal volume
of loading buffer containing 60 mM Tris–HCl (pH 6.8), 100
mM dithiothreitol (DTT), and 2% SDS and then boiled for
5 min, sonicated for 10 s, and centrifuged at 12,000 g for
5 min. The supernatant was loaded onto a 10% discon-
tinuous SDS-polyacrylamide gel, and the proteins were
fractionated by electrophoresis at 35 mA before transfer
onto nylon membrane in Tris–glycine–methanol buffer at
50 mA for 6 h. The filter strips were blocked in 5% nonfat
milk powder in PBS for 1 h at 23°C and then incubated in
the appropriate first antibody solution for 1 h at 23°C with
agitation and washed three times in PBS plus 0.3%
Tween 20 (PBS-T), followed by incubation with horserad-
ish peroxidase (HRP)-labeled donkey anti-rabbit or
sheep anti-mouse antibody (used at a dilution of
1:10,000). Finally the blots were then washed three times
with PBS-T and incubated with ECL-fluorescent devel-
oper (RPN 2106; Amersham) before exposure to x-ray film
for 30 s. First antibodies that were used included mouse
mAb against GST at 1:300 dilution and or rabbit IE2
antipeptide antibody (pAb) antiserum P3 against amino
acids 367–382 (Pizzorno et al., 1991) diluted 1:40 in PBS
containing 5% nonfat milk powder and 0.3% Tween 20.
Nuclear extract preparation
For nuclear extract preparation, a modified Dignam
protocol was used (Chiou et al., 1993; Roberts et al.,
1988; Shapiro et al., 1988). Subconfluent HeLa cells,
mock or DNA-transfected Vero cells, HCMV infected or
uninfected HF cells, or U373 (AN) or (A45) astrocytoma
cell cultures were harvested and washed in PBS-A. Two
packed cell volumes [10 mM HEPES buffer, pH 7.9, con-
taining 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 13
protease inhibitor cocktail (0.1 mM TPCK, 1.0 mM TLCK,
0.5 mM PMSF, and 1 mg/ml concentration each of pep-
statin and leupeptin)] were added at 4°C to resuspend
and swell the cells for 10 min. Five to 10 strokes in a
Dounce homogenizer type B (7- to 15-ml volume) were
used to rupture the cell membranes, and the nuclei were
collected by pelleting in a centrifuge at 1000 g at 4°C for
10 min. The pellet was resuspended in high salt buffer
containing 20 mM HEPES, pH 7.9, 25% (v/v) glycerol, 0.42
M NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, and 0.5 mM DTT
plus 13 protease inhibitor cocktail and lysed by constant
rocking at 4°C for 1 h. The debris was separated from the
nuclear protein extract by centrifugation at 16,000 g and
4°C for 30 min. The clear supernatant was aliquoted into
prechilled tubes, flash-frozen in liquid nitrogen, and
stored at 280°C for later use. For the HSV-1 IE175
DNA-binding activity, a nuclear extract from Vero cells
transfected with the wild-type IE175(ICP4) gene in plas-
mid pGH114 (Mullen et al., 1995) was used. In all cases,
samples containing 5–10 mg of total protein per lane
were used for EMSA experiments.
Labeling of synthetic oligonucleotides
Single-stranded oligonucleotides (usually 26 bp long
with 59 BamHI and BglII compatible overhangs) were
synthesized and purified by HPLC (Johns Hopkins Uni-
versity, School of Hygiene Oligonucleotide Synthesis Fa-
cility). Equal amounts (10 nmol) of each complementary
strand were annealed together in 100 ml of STE (100 mM
NaCl, 10 mM Tris–HCl, pH 8.0, 1 mM EDTA) by incubation
at 85°C for 10 min, followed by gradual cooling to room
temperature. The annealed products contained 4-bp
GATC 59 overhangs for cloning purposes to create
BamHI and BglII sites. The end-labeling reaction (to
create complete double-stranded 30 mers) was carried
out by incubation of 10–20 pmol (2 ml) of the annealed
oligonucleotides in a Klenow DNA polymerase reaction
cocktail mix [1 ml of reaction buffer-2 (BRL); 10 mM
concentration each of dGTP, dCTP, and dTTP; 1 U/ml of
Klenow fragment of polynucleotide polymerase; 10 mCi of
[a-32P]dATP, and 6 ml of distilled water) at 20°C for 15
min. The unused isotope and free nucleotides were re-
moved from the labeled products by elution through a
G-25 Sephadex column. The standard CRS wild-type and
CRS 11/ins binding site probes used were the annealed
30- and 31-bp oligonucleotide pairs LGH546/547(CRS)





ACGAGCTCCCGG-39 or the 23- and 24-bp versions
LGH812/813 (CRS) and LGH 885/886 (DCRS) containing
the sequences 59-GATCTCGTTTAGTGAACCGTCA G-39
and 59-GATCCTACGGTTCACTAAACGA-39 or 59-
GATCTCGTTTAGG*TGAACCGTCAG-39 and 59-GAT-
CCTGACGGTTCC*ACTAAACGA-39, respectively. The rel-
evant sequences of other oligonucleotide motifs used for
IE2 EMSA binding experiments are shown in Figs. 7A,
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8A, 8B, and 10. The IE175 binding site probe used as a
positive control for EMSA represented the wild-type
IE175 promoter cap site motif in the annealed 30-bp
oligonucleotide pair LGH47/48 containing the se-
quences 59-GATCCATGGGGGAATCGTCACTGCCGCT-
GA-39 and 59-GATCTCAGCGGCAGTGACGATTCCC-
CCATG-39 (Roberts et al., 1988).
EMSA
In general, EMSA experiments were performed at
20°C. Protein–DNA-binding reaction mixtures (25 ml)
containing 10 mM Tris–HCl (pH 7.5), 0.5 mM DTT, 1 mM
EDTA, 0.1% Triton X-100, 5% glycerol, 50 mM KCl, 1.0 mM
MgCl2, 40 mg/ml of poly(dA-dT)/(dA-dT), and 5–10 mg of
the nuclear extract were incubated for 15 min at 20°C.
Duplex oligonucleotide probes end-labeled with
[a-32P]dATP (20,000 cpm, ;20 fmol) were then added
and incubated for 30 min at 20°C. For antibody supershift
and excess oligonucleotide competition, these reagents
were added after 15 min of preincubation with the probe
and were allowed to incubate for an additional 15 min.
The reaction mixtures were separated on 2% TBE aga-
rose gel in 0.53 Tris–borate–EDTA buffer. After electro-
phoresis at 40 mA for 1–2 h, the gels were dried in a gel
dryer on Whatman DEAE-80 paper. Free and protein-
bound DNA complexes were identified by autoradiogra-
phy and recovered by excision from the dried gels. Sam-
ples were then measured for radioactivity using an LKB
liquid scintillation counter, and the percentage of bound
versus unbound DNA was calculated. Poly(dA-dT)/
(dA-dT) and poly(dI-dC)/(dI-dC) were purchased from
Pharmacia (catalog nos. 37–7880-02 and 27–7870-02),
and distamycin (Sigma D6135) and chromomycin-A3
(Sigma C2659) were prepared as 1 mM stock solutions.
Antibodies used for supershift experiments were rabbit
pAb antipeptide sera P4 directed against IE2 codons
550–564 (Pizzorno et al., 1991), mAb 58S directed against
the HSV IE175 protein (Roberts et al., 1988), and nonspe-
cific IgG for staphylococcal Protein A complexes.
Phosphorylation and dephosphorylation of GST/IE2
fusion proteins
Approximately 5 mg of the appropriate GST/IE2 fusion
proteins was incubated in the presence of 50 mM Tris–
HCl, pH 7.4, 100 mM ATP, 1 U of the catalytic subunit of
PKA (Sigma catalog no. P2645), 10 mM MgCl2, and 5 mM
DTT for 15 min at 37°C. For protein labeling by PKA,
[g-32P]ATP (5000–6000 cpm/pmol) was added. The reac-
tion was stopped by boiling for 5 min in the presence of
Laemmli’s buffer containing 10 mM EDTA and 20 mM
DTT. Nonhydrolyzable [g-35S]ATP (Sigma) was substi-
tuted in some experiments. Samples were analyzed di-
rectly by SDS–PAGE and autoradiography or used in
EMSA experiments. CKII and p34cdc2/cyclin B protein
kinase were obtained from New England Biolabs.
In dephosphorylation experiments, the GST/IE2 was
prephosphorylated in the presence of 10 mM ATP and
PKA by incubation at 30°C for 30 min. Free ATP was
removed from the reaction mixture by elution through
G-25 column. The phosphorylated proteins and crude
nuclear extracts were then incubated with 1 U of BAP
(Sigma) at 37°C for 15 min. The reaction was stopped by
the addition of 1 mM Na2PO4 to the reaction mixture.
Proteins were then analyzed for DNA binding activity by
using standard EMSA procedures.
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